FDA Vaccine Chief Exits Again, and Washington Smells Like Burnt Charcoal

I can smell it from here: that overheated D.C. aroma, like somebody left the rulebook too close to the smoker and now the whole neighborhood tastes like panic. When the referee keeps walking off the field, the crowd does not get calmer. It gets louder.

Prasad is leaving again

According to the Associated Press, Dr. Vinay Prasad, the Food and Drug Administration’s top vaccine regulator, is leaving for the second time in less than a year. FDA Commissioner Marty Makary told staff in an email that Prasad will depart at the end of April and return to his academic job at the University of California, San Francisco. Axios reported an HHS spokesperson confirmed the exit, and the Wall Street Journal first reported it.

The “revolving door” turns into a rotisserie

AP reported Prasad was previously pushed out briefly in July after running afoul of biotech executives, patient groups, and even some conservative allies of President Donald Trump. Then he returned less than two weeks later with backing from Health Secretary Robert F. Kennedy Jr. and Makary.

That is not stability. That is whiplash. That is an agency doing donuts in the parking lot while every interested party watches the skid marks and tries to spin the story.

Two flashpoints that went public

• Moderna’s mRNA flu vaccine: AP reported Prasad initially refused to allow the FDA to even review the application, an unusual move that pushed Moderna to publicly challenge the decision. About a week after it became public, AP reported the FDA reversed course and said it would accept the shot for review, pending an additional study.
• UniQure and Huntington’s disease gene therapy: AP reported the company said the FDA was demanding a new trial involving sham surgery for some patients, which UniQure argued raised ethical concerns and contradicted earlier guidance. AP also reported the FDA held an unusual press conference to criticize the therapy and defend its request for an additional study. In that same report, a senior FDA official speaking anonymously reportedly called the company’s original study “stone cold negative.”

What this says about Washington right now

AP reported Prasad’s tenure mixed talk of making reviews faster and easier with new warnings and study requirements for some products, including COVID shots that have been a political flash point. That tension did not vanish just because one guy is packing up his office plants.

Bottom line

Prasad leaving again is not just a staffing note. It is a flare that says the fight over health policy, corporate pressure, and agency power is still raging inside the federal machine. If the FDA is going to earn trust, it cannot look like it is making high-stakes calls in public brawls and real-time reversals.

So here is my smoke-and-flags sermon: stop treating the FDA like a customer service desk for the loudest people in the room. Make the standards clear. Make the process consistent. And make the bureaucracy explain itself like it works for the country, because it does.